Deal values cancer drug developer Nuvalent at US$124 (RM503) per shareThat is a 40 per cent premium to the US-listed firm’s close yesterdayGSK CEO Miels says deals expands ...
GSK has agreed to buy US biopharmaceutical business IDRx in a deal worth up to $1.15billion (£1billion). Under the agreement, GSK will pay $1billion upfront to acquire the Massachusetts-based firm, ...
GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion. By Rebecca Robbins The British drug maker GSK said on Wednesday that it ...
(Alliance News) - GSK PLC on Tuesday said it has agreed to US-based cancer drug developer Nuvalent Inc for USD10.6 billion. The announcement confirmed a Financial Times report published early Tuesday.
GSK plc (NYSE:GSK) agreed to acquire IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. Under the agreement, GSK ...
May 13 (Reuters) - Britain's GSK (GSK.L), opens new tab and drug developer iTeos Therapeutics (ITOS.O), opens new tab said on Tuesday they have stopped developing an experimental lung cancer drug, ...
LONDON, June 9 (Reuters) - GSK has agreed to buy U.S.-listed cancer drug developer Nuvalent for $10.6 billion in its largest deal in more than a decade, marking a strategic shift under new CEO Luke ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results